Answers are grounded in this paper and cite their sources.
Background: Knee osteoarthritis (KOA) is a debilitating degenerative joint disease that significantly reduces quality of life, with no definitive treatments currently available. Recent research has highlighted the pathogenic role of hypoxia-inducible factor-2α (HIF-2α) in KOA. Belzutifan, originally developed as an anti-cancer drug, has demonstrated substantial therapeutic promise as a HIF-2α inhibitor for KOA treatment. Objective: This study aimed to investigate the underlying mechanism by which belzutifan alleviates KOA through both in vivo and in vitro experiments. Methods: Initially, Safranin O-fast green staining and immunohistochemistry (IHC) were conducted to assess the chondroprotective effects of belzutifan in a rat KOA model. Bioinformatic analyses and molecular docking simulations were then performed to predict the potential involvement of HIF-2α in chondrocyte injury associated with KOA. Finally, primary rat chondrocytes were isolated and cultured to validate the downstream signaling pathway targeted by belzutifan treatment in vitro. Results: In vivo, belzutifan significantly inhibited the expression levels of matrix metalloproteinase-13 (MMP-13) and HIF-2α in articular cartilage of KOA model rats, enhanced collagen type II alpha 1 chain (COL2A1) expression, and demonstrated a protective effect on articular cartilage. Bioinformatic analysis of the GSE104794 microarray dataset indicated that HIF-2α overexpression in chondrocytes activates ferroptosis signaling, notably upregulating the ferroptosis master regulator acyl-CoA synthetase long-chain family member 4 (ACSL4). Thus, we hypothesized that belzutifan exerts its therapeutic effect on KOA by inhibiting chondrocyte ferroptosis via the HIF-2α/ACSL4 axis. This hypothesis was confirmed through in vitro experiments, showing that belzutifan effectively reduced IL-1β-induced reactive oxygen species (ROS) and malondialdehyde (MDA) levels in chondrocytes, suppressed the expression of pro-inflammatory cytokines, and enhanced mitochondrial membrane potential. Furthermore, belzutifan significantly downregulated MMP-13 and ACSL4 expression while upregulating COL2A1 and glutathione peroxidase 4 (GPX4) expression. ACSL4 overexpression reversed these beneficial effects, confirming the involvement of the HIF-2α/ACSL4/ferroptosis pathway in belzutifan action. Conclusion: Belzutifan attenuates cartilage damage and slows KOA progression by suppressing chondrocyte ferroptosis mediated by the HIF-2α/ACSL4 axis. These results underscore belzutifan as a promising therapeutic candidate for KOA.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: